Paper Details

  1. Home
  2. Paper Details

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.

Author: AulH C, BüchnerT, FischerJ, HiddemannW, KuseR, LudwigW D, RühlH, UrbanitzD, VaupelH A, ZeileG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 576 adults with acute myeloid leukemia (AML) found that intensive induction therapy with a combination of 6-thioguanine, cytosine arabinoside, and daunorubicin (TAD9) resulted in a 65% complete remission (CR) rate. While post-remission treatment protocols varied, the study found that maintenance chemotherapy significantly improved long-term remission rates. Patients receiving maintenance therapy had a 30% continuous remission rate at 2.5 years compared to 17% for those not receiving maintenance (P=0.003). These findings highlight the importance of both intensified induction therapy and continued myelosuppressive treatment for achieving long-term remission in AML.
Paper Details　
Original Abstract of the Article :
In two multicenter trials, a total of 576 patients with acute myeloid leukemia (AML) were treated and found to be evaluable. Two hundred forty-two patients were in a 1978 pilot study and 334 patients were in a 1982 randomized study. Ages were between 15 and 78 years (median, 48). The uniform remissi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1985.3.12.1583

データ提供：米国国立医学図書館（NLM）

Fighting Leukemia: Intensified Therapy for a Stronger Response

This research delves into the [oncology] realm and examines the effectiveness of intensified induction and consolidation chemotherapy for acute myeloid leukemia (AML). The study, involving [576] patients, analyzes data from two multicenter trials conducted by the German AML Cooperative Group. The study found that a uniform remission induction therapy consisting of a 9-day combination of 6-thioguanine (TG), cytosine arabinoside (ARA-C), and daunorubicin (DNR) achieved complete remission in approximately 65% of patients. The study also evaluated the impact of post-remission treatment, finding that patients receiving treatment during remission had a significantly higher probability of remission compared to those who did not receive further therapy. The study found that consolidation therapy with TAD9 improved remission duration compared to no maintenance therapy.

Intensified Treatment: A Strategy for Better Outcomes

The study provides strong evidence for the effectiveness of intensified induction and consolidation chemotherapy in AML. The findings suggest that this approach significantly improves complete remission rates and prolongs remission duration. The study also highlights the importance of continued treatment during remission to prevent relapse and improve long-term outcomes.

A Beacon of Hope: Advancing AML Treatment

AML is a serious and often aggressive form of cancer. This study offers valuable insights into more effective treatment strategies for this disease. The findings underscore the importance of early and aggressive treatment, including intensified induction and consolidation chemotherapy, to improve remission rates and long-term survival. Further research is needed to refine these treatment approaches and identify potential targets for more personalized therapies.

Dr.Camel's Conclusion

Leukemia is a harsh desert, but with careful navigation and a strategic approach, we can find pathways to improved survival. This research highlights the effectiveness of intensified therapy, offering hope for patients and providing direction for future research in the fight against AML.

Date :
  1. Date Completed 1986-01-16
  2. Date Revised 2020-12-22
Further Info :

Pubmed ID

3906048

DOI: Digital Object Identifier

10.1200/JCO.1985.3.12.1583

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.